Morgan Stanley lowered the firm’s price target on Regenxbio (RGNX) to $17 from $18 and keeps an Overweight rating on the shares after the company reported fourth quarter results. Investor inbounds point to regulatory updates as potentially meaningful catalysts at this point, the firm noted. Trading at an enterprise value of approximately $200M, Morgan Stanley sees risk/reward as skewed positively into material catalysts across multiple programs this year.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGNX:
- Regenxbio price target lowered to $42 from $45 at Stifel
- Regenxbio reports Q4 EPS ($1.30) vs. ($1.01) last year
- FDA review process for accelerated approval narrows, less predictable, WSJ says
- RGNX Earnings this Week: How Will it Perform?
- LEVI & KORSINSKY, LLP: RGNX DISCLOSURE TIMELINE REVEALS PATTERN OF ALLEGED INVESTOR HARM